{
    "ticker": "ACLX",
    "name": "Acelyrin, Inc.",
    "description": "Acelyrin, Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapeutics for patients with serious and life-threatening diseases. Founded in 2021, Acelyrin is dedicated to addressing unmet medical needs by harnessing advanced scientific research and cutting-edge technology. The company\u2019s lead product candidate, izokibep, is a monoclonal antibody designed to treat a range of autoimmune diseases, including psoriasis and ankylosing spondylitis. Acelyrin aims to improve the quality of life for patients through novel treatment options that offer enhanced efficacy and safety profiles. The company is committed to sustainable practices and ethical research methods, with a team of experienced professionals from the pharmaceutical and biotechnology sectors. Acelyrin is headquartered in La Jolla, California, and is focused on expanding its pipeline to include additional therapeutic candidates that can provide significant benefits to patients and healthcare providers alike. The company\u2019s mission is to transform the landscape of treatment options available for autoimmune disorders and other chronic conditions, making a meaningful impact on the lives of those affected by these diseases.",
    "industry": [
        "Biopharmaceutical",
        "Healthcare"
    ],
    "headquarters": "La Jolla, California, USA",
    "founded": "2021",
    "website": "https://www.acelyrin.com",
    "ceo": "Shaun E. M. O'Leary",
    "social_media": {
        "twitter": "https://twitter.com/acelyrin",
        "linkedin": "https://www.linkedin.com/company/acelyrin/"
    },
    "investor_relations": "https://ir.acelyrin.com",
    "key_executives": [
        {
            "name": "Shaun E. M. O'Leary",
            "position": "CEO"
        },
        {
            "name": "Travis C. H. B. McFarland",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "Izokibep"
            ]
        }
    ],
    "seo": {
        "meta_title": "Acelyrin, Inc. | Innovative Biopharmaceuticals for Serious Diseases",
        "meta_description": "Acelyrin, Inc. is focused on developing innovative therapeutics for serious diseases, including autoimmune disorders. Learn about their mission and product pipeline.",
        "keywords": [
            "Acelyrin",
            "Biopharmaceuticals",
            "Autoimmune Diseases",
            "Therapeutics",
            "Izokibep"
        ]
    },
    "faq": [
        {
            "question": "What is Acelyrin known for?",
            "answer": "Acelyrin is known for its innovative therapeutics aimed at treating serious autoimmune diseases."
        },
        {
            "question": "Who is the CEO of Acelyrin?",
            "answer": "Shaun E. M. O'Leary is the CEO of Acelyrin, Inc."
        },
        {
            "question": "Where is Acelyrin headquartered?",
            "answer": "Acelyrin is headquartered in La Jolla, California, USA."
        },
        {
            "question": "What is Acelyrin's main product?",
            "answer": "Acelyrin's main product candidate is izokibep, aimed at treating autoimmune diseases."
        },
        {
            "question": "When was Acelyrin founded?",
            "answer": "Acelyrin was founded in 2021."
        }
    ],
    "competitors": [
        "AMGN",
        "ABBV",
        "REGN"
    ],
    "related_stocks": [
        "GILD",
        "VRTX",
        "BMY",
        "JNJ"
    ]
}